Female non-insulin-dependent diabetics have a high prevalence of gallstones. Treatment of hyperlipidaemia in these patients may modify the risk. Seventeen female non-insulin-dependent diabetics (age 35-65) were treated with simvastatin (n = 10) or bezafibrate (n = 7) and had the cholesterol saturation index (CSI) of bile and gall-bladder emptying measured before and after 3 months therapy. In both groups, there was a significant reduction in serum cholesterol following treatment. The mean pretreatment cholesterol saturation indices of bile did not differ between the two groups but, after 3 months therapy, there was a highly significant difference in CSI between the bezafibrate group (2.0 +/- 0.33) and the simvastatin group (1.1 +/- 0.14) P < 0.002. Whereas the increase in the CSI (42%) observed with bezafibrate therapy was significant, the decrease in the simvastatin group (14%) was only significant in those whose pretreatment cholesterol saturation indices were elevated. Despite the differences in CSI observed between the two treatment groups, no changes in gall-bladder emptying were detected.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1440-1746.1994.tb01272.xDOI Listing

Publication Analysis

Top Keywords

gall-bladder emptying
12
female non-insulin-dependent
12
non-insulin-dependent diabetics
12
cholesterol saturation
12
simvastatin bezafibrate
8
months therapy
8
pretreatment cholesterol
8
saturation indices
8
group +/-
8
simvastatin group
8

Similar Publications

Aim: to investigate hepatopancreatoduodenectomy (HPD) application in gallbladder carcinoma (GBC) and compare it to radical cholecystectomy (RC) regarding patients' characteristics, surgical outcome and survival.

Methods: Patients treated in our center were included. Three groups (HPD, RC, no-surgery) were compared.

View Article and Find Full Text PDF

Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual GLP-1- and glucose-dependent insulinotropic polypeptide receptor co-agonist tirzepatide (referred to here collectively as "GLP-1-based therapy") are incretin-based therapies being used increasingly in the management of both type 2 diabetes and obesity. They are now recognized to have beneficial effects beyond improved glycemic control and weight loss, including cardiovascular and renal protection. GLP-1-based therapy also slows gastric emptying, which has benefits (lowering postprandial glucose), but also potential risks (eg, hypoglycemia in individuals on insulin or sulphonylurea therapy).

View Article and Find Full Text PDF

Design: The hormone secretin, best known for regulating pH in the duodenum, has anorectic properties in mice proposedly mediated via secretin-induced brown adipose tissue (BAT) activation. We investigated the effects of exogenous secretin on ad libitum food intake, BAT activity, and postprandial physiology in healthy male volunteers.

Methods: In a randomized, placebo-controlled, double-blind, crossover study, 25 healthy men underwent two 5-h i.

View Article and Find Full Text PDF
Article Synopsis
  • - The study examined gallbladder emptying and GLP-1 hormone responses in women with gestational diabetes mellitus (GDM) during pregnancy and postpartum to understand GDM's impact on these processes.
  • - Twenty women (15 with GDM and 15 with normal glucose tolerance) participated in mixed meal tests, revealing no differences in gallbladder emptying or GLP-1 responses between the two groups during pregnancy or after.
  • - Results showed that while gallbladder volume and emptying increased significantly during pregnancy, GLP-1 responses decreased, indicating that changes in gallbladder function may not be the main factors contributing to reduced GLP-1 levels in women with GDM.
View Article and Find Full Text PDF

Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks.

Obes Pillars

December 2024

Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic, Jacksonville, FL, USA.

Background: This review investigates the side effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) like liraglutide, semaglutide, and tirzepatide, medications known for their efficacy in promoting weight loss among individuals with obesity. The rationale is rooted in understanding the balance between their therapeutic benefits and associated risks.

Methods: This was a comprehensive clinical review, including systematic reviews, meta-analyses, randomized controlled trials (RCTs), and cohort studies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!